Magnetic resonance spectroscopy of breast cancer: Current techniques and clinical applications

Cancer Imaging

Volumn , Issue , 2008, Pages 407-415

  Meisamy, Sina ^a   Bolan, Patrick J ^a   Garwood, Michael ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884925011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374212-4.50045-6     Document Type: Chapter

References (35)

1. Bakken I.J., Gribbestad I.S., Singstad T.E., Kvistad K.A. External standard method for the in vivo quantification of cholinecontaining compounds in breast tumors by proton MR spectroscopy at 1.5 Tesla. Magn. Reson. Med. 2001, 46:189-192.
2. 1H MRS of breast lesions. Magn. Reson. Med. 2002, 48:215-222.
3. 1H MRS at 4 Tesla. Magn. Reson. Med. 2004, 52:1239-1245.
4. 1H MR spectroscopy. Magn. Reson. Med. 2003, 50:1134-1143.
5. Cavassila S., Deval S., Huegen C., van Ormondt D., Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001, 14:278-283.
6. Cecil K.M., Schnall M.D., Siegelman E.S., Lenkinski R.E. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res. Treat. 2001, 68:45-54.
7. Chagpar A.B., Middleton L.P., Sahin A.A., Dempsey P., Buzdar A.U., Mirza A.N., Ames F.C., Babiera G.V., Feig B.W., Hunt K.K., Kuerer H.M., Meric-Bernstam F., Ross M.I., Singletary S.E. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann. Surg. 2006, 243:257-264.
8. Choyke P.L., Dwyer A.J., Knopp M.V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging. 2003, 17:509-520.
9. Delille J., Slanetz P.J., Yeh E.D., Halpern E.F., Kopans D.B., Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imagingpilot study. Radiology 2003, 228:63-69.
10. Esserman L., Kaplan E., Partridge S., Tripathy D., Rugo H., Park J., Hwang S., Kuerer H., Sudilovsky D., Lu Y., Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neodjuvant chemotherapy in stage III breast cancer. Ann. Surg. Oncol. 2001, 8:549-559.
11. Garwood M., DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001, 153:155-177.
12. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 15:4270-4276.
13. Gribbestad I.S., Sitter B., Lundgren S., Krane J., Axelson D. Metabolic composition in breast tumors examined by proton nuclear resonance spectroscopy. Anticancer Res. 1999, 19:1737-1746.
14. Herrada J., Iyer R.B., Atkinson E.N., Sneige N., Buzdar A.U., Hortobagyi G.N. Relative value of physical examination, mammograohy, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breas carcinoma. Clin. Cancer Res. 1997, 3:1565-1569.
15. Huang W., Fisher P.R., Dulaimy K., Tudorica L.A., O'Hea B., Button T.M. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004, 232:585-591.
16. Jacobs M.A., Barker P.B., Bottomley P.A., Bhujwalla Z., Bluemke D.A. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J. Magn. Reson. Imaging 2004, 19:68-75.
17. Jagannathan N.R., Kumar M., Seenu V., Coshic O., Dwivedi S.N., Julka P.K., Srivastava A., Rath G.K. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 2001, 84:1016-1022.
18. Jordan B.F., Black K., Robey I.F., Runquist M., Powis G., Gillies R.J. Metabolite changes in HT-29 xenograft tumors following HIF-Ialpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed. 2005, 18:430-439.
19. Katz-Brull R., Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res. 1996, 16:1375-1380.
20. Katz-Brull R., Lavin P.T., Lenkinski R.E. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002, 94:1197-1203.
21. Kvistad K.A., Bakken I.J., Gribbestad I.S., Ehrnholm B., Lundgren S., Fjosne H.E., Haraldseth O. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J. Magn. Reson. Imaging 1999, 10:159-164.
22. Leach M.O., Verrill M., Glaholm J., Smith T.A., Collins D.J., Payne G.S., Sharp J.C., Ronen S.M., McCready V.R., Powles T.J., Smith I.E. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998, 11:314-340.
23. Mackinnon W.B., Barry P.A., Malycha P.L., Gillett D.J., Russell P., Lean C.L., Doran S.T., Barraclough B.H., Bilous M., Mountford C.E. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997, 204:661-666.
24. Manton D.J., Chaturvedi A., Hubbard A., Lind M.J., Lowry M., Maraveyas A., Pickles M.D., Tozer D.J., Turnbull L.W. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br. J. Cancer 2006, 13:427-435.
25. Meisamy S., Bolan P.J., Baker E.H., Pliss R.L., Gulbahce E., Everson L.I., Nelson M.T., Emory T.H., Tuttle T.M., Yee D., Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4T. Radiology 2004, 233:424-431.
26. 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 2005, 236:465-475.
27. Negendank W.G., Brown T.R., Evelhoch J.L., Griffiths J.R., Liotta L.A., Margulis A.R., Morrisett J.D., Ross B.D., Shtern F. Proceedings of a National Cancer Institute workshop: MR spectroscopy and tumor cell biology. Radiology 1992, 185:875-883.
28. Orel S.G., Schnall M.D. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001, 220:13-30.
29. Rieber A., Brambs H.J., Gabelmann A., Heilmann V., Kreienberg R., Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 2002, 12:1711-1719.
30. Roebuck J.R., Cecil K.M., Schnall M.D., Lenkinski R.E. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998, 209:269-275.
31. Schnall M.D., Blume J., Bluemke D.A., DeAngelis G.A., DeBruhl N., Harms S., Heywang-Kobrunner S.H., Hylton N., Kuhl C.K., Pisano E.D., Causer P., Schnitt S.J., Thickman D., Stelling C.B., Weatherall P.T., Lehman C., Gatsonis C.A. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 2006, 238:42-53.
32. Sitter B., Sonnewald U., Spraul M., Fjosne H.E., Gribbestad I.S. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002, 15:327-337.
33. Slotboom J., Boesch C., Kreis R. Versatile frequency domain fitting using time domain models and prior knowledge. Magn. Reson. Med. 1998, 39:899-911.
34. Tse G.M., Cheung H.S., Pang L.M., Chu W.C., Law B.K., Kung F.Y., Yeung D.K. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am. J. Roentgenol. 2003, 181:1267-1272.
35. Vaughan J.T., Garwood M., Collins C.M., Liu W., DelaBarre L., Adriany G., Andersen P., Merkle H., Goebel R., Smith M.B., Ugurbil K. 7T vs. 4T: RF power, homogeneity, and signal-to-noise comparison in head images. Magn. Reson. Med. 2001, 46:24-30.